Icotinib
- Generic Name
- Icotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H21N3O4
- CAS Number
- 610798-31-7
- Unique Ingredient Identifier
- 9G6U5L461Q
- Background
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
...
- Indication
Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.
- Associated Conditions
- -
- Associated Therapies
- -
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 23
- Registration Number
- NCT06517953
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- Wu Nan
- Target Recruit Count
- 90
- Registration Number
- NCT05514314
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 45
- Registration Number
- NCT05132985
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-11-03
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 27
- Registration Number
- NCT05104788
- Locations
- 🇨🇳
BeijingCancerH, Beijing, China
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05007938
- Locations
- 🇨🇳
Feng Ye, Xiamen, Fujian, China
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2021-03-15
- Target Recruit Count
- 206
- Registration Number
- NCT04797806
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 272
- Registration Number
- NCT04575415
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2019-08-15
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 296
- Registration Number
- NCT04058704
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2019-06-20
- Target Recruit Count
- 70
- Registration Number
- NCT03992885
- Locations
- 🇨🇳
Department of Pulmonary Medical Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
Adjuvant Chemotherapy With or Without Intercalated Icotinib
- Conditions
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 174
- Registration Number
- NCT03983811
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.